1. Goldberg JF. Perspectives on the success rate of current antidepressant pharmacotherapy. Expert Opin Pharmacother. 2022 Nov;23(16):1781-1791. doi: 10.1080/14656566.2022.2138333. Epub 2022 Oct 24. PMID: 36259350. [cited 2025 Nov 28]
2. Kennedy SH. Treating each and every depressed patient. J Psychopharmacol. 2008 Sep;22(7 Suppl):19-23. doi: 10.1177/0269881108093270. PMID: 18753279. [cited 2025 Nov 28]
3. Chauhan S, Tiwari A, Verma A, Padhan PK, Verma S, Gupta PC. Exploring the Potential of Saffron as a Therapeutic Agent in Depression Treatment: A Comparative Review. Yale J Biol Med. 2024 Sep 30;97(3):365-381. doi: 10.59249/XURF4540. PMID: 39351321; PMCID: PMC11426294. [cited 2025 Nov 28]
4. Dai L, Chen L, Wang W. Safety and Efficacy of Saffron (Crocus sativus L.) for Treating Mild to Moderate Depression: A Systematic Review and Meta-analysis. J Nerv Ment Dis. 2020 Apr;208(4):269-276. doi: 10.1097/NMD.0000000000001118. PMID: 32221179. [cited 2025 Nov 28]
5. Niarchou E, Roberts LH, Naughton BD. What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: A systematic review. J Psychopharmacol. 2024 Feb;38(2):127-136. doi: 10.1177/02698811231224171. PMID: 38344912; PMCID: PMC10863360. [cited 2025 Nov 28]
6. Baculio et al, A Systematic Review on the Effectiveness of Cognitive Behavioral Therapy (CBT) Compared to Antidepressant Medications on Adults with Depressive Disorder published in the International Journal for Multidisciplinary Research Volume 7, Issue 1, January-February 2025 [cited 2025 Nov 28]
7. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, Gorwood P, Ho R, Kasper S, Kennedy SH, Ly-Uson J, Mansur RB, McAllister-Williams RH, Murrough JW, Nemeroff CB, Nierenberg AA, Rosenblat JD, Sanacora G, Schatzberg AF, Shelton R, Stahl SM, Trivedi MH, Vieta E, Vinberg M, Williams N, Young AH, Maj M. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023 Oct;22(3):394-412. doi: 10.1002/wps.21120. PMID: 37713549; PMCID: PMC10503923. [cited 2025 Nov 28]
8. FDA drug label Lexapro/escitalopram oxalate published online, revised 1/2017 [cited 2025 Nov 28]
9. FDA drug label Wellbutrin/bupropion hydrochloride published online, revised 2017 [cited 2025 Nov 28]
10. FDA label Zoloft/sertraline hydrochloride published online, revised December 2016 [cited 2025 Nov 28]
11. FDA drug label Prozac/fluoxetine published online revised Aug 2023 [cited 2025 Nov 28]
12. Marazziti D, Mucci F, Tripodi B, Carbone MG, Muscarella A, Falaschi V, Baroni S. Emotional Blunting, Cognitive Impairment, Bone Fractures, and Bleeding as Possible Side Effects of Long-Term Use of SSRIs. Clin Neuropsychiatry. 2019 Apr;16(2):75-85. PMID: 34908941; PMCID: PMC8650205. [cited 2025 Nov 28]
13. Barnhart WJ, Makela EH, Latocha MJ. SSRI-induced apathy syndrome: a clinical review. J Psychiatr Pract. 2004 May;10(3):196-9. doi: 10.1097/00131746-200405000-00010. PMID: 15330228. [cited 2025 Nov 28]
14. Padala PR, Padala KP, Majagi AS, Garner KK, Dennis RA, Sullivan DH. Selective serotonin reuptake inhibitors-associated apathy syndrome: A cross sectional study. Medicine (Baltimore). 2020 Aug 14;99(33):e21497. doi: 10.1097/MD.0000000000021497. PMID: 32871995; PMCID: PMC7437849. [cited 2025 Nov 28]
15. Barbosa Eyler GE. ¿Apatía o embotamiento emocional por ISRS? Una revisión de la literatura [Embotional Blunting or apathy by SSRI? A sistematic review about their emotional effects]. Vertex. 2023 Oct 10;34(161, jul.-sept.):61-66. Spanish. doi: 10.53680/vertex.v34i161.486. PMID: 37819063. [cited 2025 Nov 28]
16. Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013 Oct 28;8(4):169-76. PMID: 26005484; PMCID: PMC4434967. [cited 2025 Nov 28]
17. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults – a Swedish nationwide study. Br J Clin Pharmacol. 2016 Apr;81(4):773-83. doi: 10.1111/bcp.12829. Epub 2016 Jan 11. PMID: 26574175; PMCID: PMC4799929. [cited 2025 Nov 28]
18. Montvilaitė R. Antidepressant Prescription to Children/Adolescents and Its Effects on the Cardiovascular System, Comprising the Actual Questions of Periodicity of the Checkups, Cooperation among Pediatricians, Family Doctors, Cardiologists and Children-Adolescent Psychiatrists. Acta Med Litu. 2025;32(1):52-63. doi: 10.15388/Amed.2025.32.1.15. Epub 2025 Feb 18. PMID: 40641530; PMCID: PMC12239188. [cited 2025 Nov 28]
19. FDA FAERS Reporting System published online since 2004 [cited 2025 Nov 28]
20. Liao H, Rosenthal DS, Kumar SC. Abnormal Thyroid Function Laboratory Results Caused by Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressant Treatment. Case Rep Psychiatry. 2023 May 11;2023:7170564. doi: 10.1155/2023/7170564. PMID: 37215167; PMCID: PMC10195165. [cited 2025 Nov 28]
21. Edinoff AN, Raveendran K, Colon MA, Thomas BH, Trettin KA, Hunt GW, Kaye AM, Cornett EM, Kaye AD. Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review. Health Psychol Res. 2022 Nov 3;10(4):39580. doi: 10.52965/001c.39580. PMID: 36425234; PMCID: PMC9680839. [cited 2025 Nov 28]